Business Context and Reporting Period
Propanc Biopharma, Inc. filed a Current Report on Form 8-K dated February 6, 2025, reporting the entry into two material definitive agreements involving the issuance of convertible promissory notes. The company, incorporated in Delaware with principal offices in Australia, intends to use the net proceeds from these financings for general working capital purposes.
Key Financial Metrics and Transaction Details
The filing details two separate convertible note transactions:
- Transaction 1 (Effective Feb 6, 2025):
- Principal Amount: $65,000
- Purchase Price: $56,000
- Interest: One-time charge of 15% ($9,750) applied at issuance.
- Total Repayment Obligation: $74,750 (Principal + Interest).
- Maturity Date: November 30, 2025.
- Repayment Schedule: Five installments beginning July 30, 2025.
- Conversion Terms: Convertible upon Event of Default at 65% of the lowest trading price during the 10 trading days prior to conversion (35% discount).
- Transaction 2 (Effective Feb 10, 2025):
- Principal Amount: $43,000
- Purchase Price: $40,000
- Interest Rate: 8% per annum.
- Maturity Date: October 7, 2025.
- Prepayment Terms: Prepayment allowed with premiums ranging from 110% to 125% of face value depending on timing; no prepayment right after 180 days.
- Conversion Terms: Fixed price of $9.00 per share (adjusts to $6.00 if stock trades below $8.00 for 5+ days); upon Event of Default, converts at lowest trading price.
The filing does not provide specific revenue, profit, cash flow, or existing debt levels for the company.
Material Changes and Obligations
The primary material change is the creation of new direct financial obligations totaling $108,000 in principal. Both notes contain strict covenants requiring the company to maintain its listing on OTC markets and comply with SEC reporting requirements. Failure to meet these conditions, along with payment defaults or insolvency, constitutes an Event of Default, triggering immediate repayment and potential conversion of debt into equity at discounted rates.
Guidance, Risks, and Contingencies
Risks and Contingencies:
- Dilution Risk: Both notes allow for conversion into common stock. The first note offers a significant discount (35%) upon default, while the second note has a fixed conversion price that adjusts downward if the stock price falls below $8.00.
- Liquidity Pressure: The first note requires significant cash outflows starting July 2025 ($37,375 initial payment). The second note restricts prepayment after 180 days, limiting flexibility.
- Compliance Risk: Default events include failure to maintain OTC listing or SEC reporting compliance.
Management Commentary: Management stated the proceeds will be used for general working capital. No specific operational guidance or future revenue outlook was provided in this filing.
Investor Verification Checklist
- Verify the company's current cash position to assess ability to meet the $37,375 payment due July 30, 2025.
- Confirm the current trading price of the common stock to evaluate potential dilution under the conversion terms of both notes.
- Review the company's compliance status with SEC reporting requirements and OTC market listing standards.
- Examine the full text of the Securities Purchase Agreements (Exhibits 10.1 and 10.2) for additional covenants not summarized in the 8-K.